NEUN Stock Chart & Stats
$0.01
$0.00(0.00%)
At close: 4:00 PM EDT
$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.01
Previous CloseN/A
Volume122.16K
Average Volume (3M)0.00
Market Cap
$8.23K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)0.5
Beta0.00
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding82,262,140
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Neurogenesis News
NEUN FAQ
What was Neurogenesis Inc’s price range in the past 12 months?
Neurogenesis Inc lowest stock price was <$0.01 and its highest was $0.01 in the past 12 months.
What is Neurogenesis Inc’s market cap?
Neurogenesis Inc’s market cap is $8.23K.
When is Neurogenesis Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Neurogenesis Inc’s earnings last quarter?
Currently, no data Available
Is Neurogenesis Inc overvalued?
According to Wall Street analysts Neurogenesis Inc’s price is currently Overvalued.
Does Neurogenesis Inc pay dividends?
Neurogenesis Inc does not currently pay dividends.
What is Neurogenesis Inc’s EPS estimate?
Neurogenesis Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neurogenesis Inc have?
Neurogenesis Inc has 82,262,140 shares outstanding.
What happened to Neurogenesis Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Neurogenesis Inc?
Currently, no hedge funds are holding shares in NEUN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neurogenesis Inc
Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm’d, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long-term use of alcohol. It also provides NeuReplenish, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of chemical stimulants; NeuRelieve, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of antianxiety drugs, and to be used in conjunction with professional support during the tapering process; and NeuSlim, which aids in the reduction of cravings (or urges) for simple carbohydrates, to reduce excessive appetite in general, and to assist in healthy moderation of nutritional needs. In addition, the company offers NeuBecalm'd/NeuRelieve Combo, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the prolonged use of prescription pain pills or from the use of opiate drugs, such as heroin or methadone, as well as used in conjunction with professional support during the tapering process. Neurogenesis, Inc. has a research collaboration with the University of Edinburgh for the development of various platform approaches to enable gene therapies. The company was founded in 1984 and is headquartered in League City, Texas.
Technical Analysis
Scinai Immunotherapeutics
―
PainReform
―
Dermata Therapeutics
―
CDT Equity
―
Virax Biolabs Group Ltd. Class A
―
